PEOPLE Living With HIV (PLHIV) and on Antiretroviral Therapy (ART) still have the option to continue taking other ART options apart from Dolutogravir (DTG) based regimens since the process is not compulsory, a ministry of health and child care (MoHCC) official has said. By Michael Gwarisa in Gweru Zimbabwe commenced its transition process from Tenovir/Lamuvidene/Efavirens to Dolutegravir (DTG) in May 2019, and the transition procedure will be completed by February 2020. Briefing a women living with HIV, Sexual Reproductive Health and Rights (SRHR) workshop organised by PAPWC/ZIM, ZWLHNF and UNAIDS,…
Read MoreDTG Won’t Be Forced On Citizens- Ministry
